Microvolt T-Wave Alternans Identifies Patients With Ischemic Cardiomyopathy Who Benefit From Implantable Cardioverter-Defibrillator Therapy
Theodore Chow, MD, FACC*,
Dean J. Kereiakes, MD, FACC*,
Cheryl Bartone, BS*,
Terri Booth, RN*,
Edward J. Schloss, MD, FACC*,
Theodore Waller, MD, FACC*,
Eugene Chung, MD*,
Santosh Menon, MD*,
Brahmajee K. Nallamothu, MD, MPH and
Paul S. Chan, MD, MSc ,*,1
* The Lindner Clinical Trial Center at the Christ Hospital and the Ohio Heart and Vascular Center, Cincinnati, Ohio
VA Ann Arbor Health Services Research and Development Center of Excellence, and the University of Michigan Medical School, Ann Arbor, Michigan.

View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Kaplan-Meier Curves Comparing Overall Survival Between Patients With and Without ICDs
Survival curves for all-cause mortality are separately depicted for the microvolt T-wave alternans (MTWA)-non-negative (A) and MTWA-negative (B) cohorts. Unadjusted results suggest a benefit with implantable cardioverter-defibrillator (ICD) therapy in the MTWA-non-negative cohort only.
|
|
|